Skip to main content

EpiShuttle: Isolation and Transportation of Infectious Disease Patients

Periodic Reporting for period 1 - EpiShuttle 2.0 (EpiShuttle: Isolation and Transportation of Infectious Disease Patients)

Reporting period: 2019-05-01 to 2020-07-31

The world has been facing an increasing number of dangerous outbreaks of infectious diseases. Examples of such are the ongoing SARS-Cov2 Pandemic, the Ebola outbreak that killed thousands in West-Africa in 2014-
2015, and the outbreaks in Democratic Republic of Congo (DRC). In addition, the emerging global threat of antimicrobial resistance is a hindrance to safe transportation of patients also outside an epidemic
setting. The transportation of patients is a crucial step in the treatment and handling of all outbreaks and represent the link in the treatment chain with particularly high risk of contamination and spread of the disease.

EpiShuttle is a product intended to mitigate these risks, to be used: 1) Transportation and isolation of patients on aircraft, ambulances, ships - any vehicle capable of safely relocating patients; 2) temporary isolation with
or without transport of patients within hospitals or other medical facilities

The objective of this SME program is to:
Apply and validate an easier disinfection system based on state-of-the-art disinfection: Hydrogen Peroxide (H2O2) fumigation technology
Design a larger version of EpiShuttle: 1) to include intended use as temporary isolation hospital bed; and 2) to cope with the requirements and market feedback where there is a need for wider units
Process the device through the US regulatory requirements and FDA approval and through the Chinese regulatory requirements and CFDA approval
The disinfection protocols, methods, equipment and validation is performed, and the procedures are about to be implemented with the EpiShuttle in clinical use.
The design process for developing modular versions of the device is ongoing, and the first POC prototypes have already been made and tested.
The EpiShuttle is already launched on the US market, and preparation for entry into other regulatory geographies are ongoing.
Through the COVID-19 pandemic, EpiShuttle has proved to be the high-end product for transporting patients with contagious disease without contaminating the environment. The additions from the SME project will broaden the market footprint with equipment and procedures for easy disinfection, with modular based versions of the device to tailor customer needs, and with access to a wide range of geographies.
The response to a pandemic or epidemic is dependent on that the health care personnel can work without a high risk of being exposed or cross-contaminate the disease to other patients. Transport isolators can be of significance in dealing with the response to epidemic. EpiShuttle has also proved to be the device of choice for transporting patients with other biohazards, such as Novochocks. The impact on society of being able to respond to crisis with contamination hazards is significant, and the EpiShuttle SME project will have implications on health-response and preparedness in the future.